These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 287556)

  • 1. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review.
    Trouet A; Sokal G
    Cancer Treat Rep; 1979 May; 63(5):895-8. PubMed ID: 287556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.
    Ferrant A; Hulhoven R; Bosly A; Cornu G; Michaux JL; Sokal G
    Cancer Chemother Pharmacol; 1979; 2(1):67-71. PubMed ID: 387279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of anthracyclines in infants in the treatment of acute lymphoblastic and non-lymphoblastic leukemias].
    Leverger G; Bancillon A; Schaison G
    Pathol Biol (Paris); 1987 Jan; 35(1):87-90. PubMed ID: 3550617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential studies of daunorubicin and adriamycin in acute nonlymphocytic leukemia.
    Wiernik PH
    Cancer Treat Rep; 1981; 65 Suppl 4():67-71. PubMed ID: 7049382
    [No Abstract]   [Full Text] [Related]  

  • 6. [Survey of anthracyclines derivatives in haematology (author's transl)].
    Jacquillat C; Weil M; Auclerc MF; Maral J; Schaison G; Boiron M; Bernard J
    Nouv Presse Med; 1978 Jun; 7(23):2061-6. PubMed ID: 673774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of detorubicin: a new anthracycline derivative.
    Jacquillat C; Auclerc MF; Weil M; Maral J; Degos L; Auclerc G; Tobelem G; Schaison G; Bernard J
    Cancer Treat Rep; 1979 May; 63(5):889-93. PubMed ID: 455330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
    Schwartz HS
    Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of daunorubicin.
    Di Marco A; Cassinelli G; Arcamone F
    Cancer Treat Rep; 1981; 65 Suppl 4():3-8. PubMed ID: 7049379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter: DNA complexes of daunorubicin (NSC-8215) and adriamycin (NSC-123127).
    Trouet A; de Duve C
    Cancer Chemother Rep; 1975; 59(2 Pt 1):260. PubMed ID: 1149004
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
    Marie JP; Thevenin D; Zittoun R
    Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.
    Trouet A; Deprez-De Campeneere D
    Cancer Chemother Pharmacol; 1979; 2(1):77-9. PubMed ID: 498424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adriamycin in the treatment of acute infantile leukemia].
    Massolo F; Galli V
    Minerva Pediatr; 1973 May; 23(16):741-7. PubMed ID: 4581975
    [No Abstract]   [Full Text] [Related]  

  • 14. [Adriamycin in the treatment of acute infantile leukemia].
    Massolo F; Galli V
    Minerva Pediatr; 1973 May; 25(16):741-7. PubMed ID: 4592614
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiotoxicity of anthracycline cytostatic agents--a proposal for routine monitoring and supportive therapy].
    Svojgrová M; Slechtová J; Hůla J
    Vnitr Lek; 1991 Feb; 37(2):151-9. PubMed ID: 2021075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations.
    Davis HL; Davis TE
    Cancer Treat Rep; 1979 May; 63(5):809-15. PubMed ID: 378369
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK; Chitnis MP; Embrey WM; Gregory EB
    Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin (NSC-123127) and its analogs.
    Henry DW
    Cancer Chemother Rep 2; 1974 Dec; 4(4):5-9. PubMed ID: 4451911
    [No Abstract]   [Full Text] [Related]  

  • 20. Daunorubicin in patients with relapsed and refractory acute nonlymphoblastic leukemia previously treated with anthracycline.
    Velu T; Debusscher L; Stryckmans P
    Am J Hematol; 1988 Mar; 27(3):224-5. PubMed ID: 3162347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.